Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
None of the three plasma biomarker was associated with NPS at baseline.
-
In general linear models lower plasma Aβ42/40 was related to lower visuospatial ability, higher total tau was related to lower episodic memory, and higher NfL was related to lower visuospatial ability and lower episodic memory.
-
Higher concentrations of plasma p-tau217, p-tau181, and NfL were correlated to higher decline speed of Mini-Mental State Examination score, and higher risk of incident dementia and AD.
-
Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer's disease (AD).
-
An accurate blood test for Alzheimer's disease that is sensitive to preclinical proteinopathy and cognitive decline has clear implications for early detection and secondary prevention.
-
Emerging plasma biomarkers of Alzheimer's disease might be non-invasive tools to trace early Alzheimer's disease-related abnormalities such as the accumulation of amyloid-beta peptides, neurofibrillary tau tangles, glial activation and neurodegeneration.
-
71/100
There were 571 participants in the normal cognition group, 625 participants in the subjective cognitive decline group, 155 participants in the objectively defined subtle cognitive decline group, 501 participants in the mild cognitive impairment group, 471 participants in Alzheimer's disease group, and 128 participants with cognitive impairment from other known causes.
-
Blood exosomes, which are extracellular vesicles secreted by living cells into the circulating blood, are regarded as a relatively noninvasive novel tool for monitoring brain physiology and disease states.
-
The best-performing MRI-free approaches had high continuous and dichotomous agreement with MRI-dependent SUVRs for Aβ PET and temporal flortaucipir (R2 ≥0.95; ± agreement ≥92%) and for Alzheimer's disease-related effect sizes; agreement was slightly lower for entorhinal flortaucipir and longitudinal slopes.
-
We found that the cognitively unimpaired amyloid-β-negative individuals had significant longitudinal tau accumulation confined to the PET Braak-like stage I (3.9%) and II (2.8%) areas.
-
71/100
It is currently unclear whether plasma biomarkers can be used as independent prognostic tools to predict changes associated with early Alzheimer's disease.
-
Mixed-effect models assessed rates of memory decline in relation to baseline plasma p-tau181, and whether plasma p-tau181 significantly predicted memory decline beyond widely available clinical and genetic data (age, sex, years of education, cardiovascular and metabolic conditions, and APOEε4 status).
-
Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the cerebral cortex.
-
Our results revealed machine learning with novel biomarkers and multiple variables may increase the sensitivity and specificity in diagnosis of AD.
-
Our systematic review shows evidence for disruptions in (night-time) melatonin levels in AD as compared to age-matched controls.
-
Blood biomarkers have great potential to advance clinical care and accelerate trials in Alzheimer's disease (AD).
-
Ten studies assessing retinal properties in dementia were included.
-
70/100
Nine proteins (amyloid-beta 42 (Aβ42), beta-secretase 1 (BACE1), glial fibrillary acidic protein (GFAP), pTau181, pTau231, pTau217, t0tal tau (MAPT), neurofilament light (NfL) and acetylcholinesterase (AChE)) robustly differed between carriers and non-carriers cross-sectionally.
-
Among the individual plasma p-tau variants, p-tau217 consistently outperformed p-tau181 and p-tau231.
-
Cognition ranged from high to early cognitive decline (median Mini-Mental State Examination [MMSE] score = 26).
-
Participants with CIND displayed lower perfusion in the PCC+PCu relative to participants who were CN, but there was no statistically significant difference between the groups in amyloid burden in this region.
-
Understanding the exact pathophysiological mechanisms underlying the involvement of triggering receptor expressed on myeloid cells 2 (TREM2) related microglia activation is crucial for the development of clinical trials targeting microglia activation at different stages of Alzheimer's disease (AD).
-
70/100
A 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria.
-
There is a need for blood biomarkers to detect individuals at different Alzheimer's disease (AD) stages because obtaining cerebrospinal fluid-based biomarkers is invasive and costly.
-
Bisecting N-acetylglucosamine correlated with tau levels (p < 0.0001).
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Levels of Retinal Amyloid-β Correlate with Levels of Retinal IAPP and Hippocampal Amyloid-β in Neuropathologically Evaluated Individuals
- Ocular static and dynamic light scattering: a noninvasive diagnostic tool for eye research and clinical practice
- Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies
- Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
- Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies
- Which plasma pTau217 assay should I use in clinical practice? Pandora's box demystified
- P-tau217 in Alzheimer's disease
- Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study
- Retinal imaging biomarkers of neurodegenerative diseases
- Decreased imaging time of amyloid PET using [18F]florbetapir can maintain quantitative accuracy